Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study.
Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study.
复制标题
单纯外照射放疗与外照射放疗联合高剂量率近距离放射治疗增强治疗高危局限性前列腺癌患者的5年生活质量：一项前瞻性多中心研究
DOI：
10.5114/jcb.2021.103580
复制
发表时间：
2021-03
影响因子：
1.4
通讯作者：
Multicentric Spanish Group of Clincally Localized Prostate Cancer: Montse Ferrer, Àngels Pont, Olatz Garin, Yolanda Pardo, Jordi Alonso, Mónica Ávila, Víctor Zamora, Ferran Guedea, Montse Ventura, Cristina Gutiérrez, Ferran Ferrer, Ana Boladeras, José Francisco Suárez, Manel Castells, Xavier Bonet, Pastor S, Carmen Bonet, Gemma Sancho, Javier Ponce de León, Joan Palou, Belén de Paula, Alai Goñi, Pablo Fernández, Ismael Herruzo, Asunción Hervás, Alfredo Ramos, Víctor Macías, Josep Solé, Marta Bonet, Alfonso Mariño, Patricia Cabrera, Maria José Ortiz
中科院分区：
文献类型：
--
作者：
Martínez E;Garin O;Pardo Y;Fernández P;Guix B;Gutiérrez C;Boladeras A;Ferrer F;Hernández T;Ayala A;Egiguren M;Fernández G;Muñoz V;Macías V;Pera J;Pont À;Ferrer M;Guedea F;Multicentric Spanish Group of Clinically Localized Prostate Cancer;Multicentric Spanish Group of Clincally Localized Prostate Cancer: Montse Ferrer, Àngels Pont, Olatz Garin, Yolanda Pardo, Jordi Alonso, Mónica Ávila, Víctor Zamora, Ferran Guedea, Montse Ventura, Cristina Gutiérrez, Ferran Ferrer, Ana Boladeras, José Francisco Suárez, Manel Castells, Xavier Bonet, Pastor S, Carmen Bonet, Gemma Sancho, Javier Ponce de León, Joan Palou, Belén de Paula, Alai Goñi, Pablo Fernández, Ismael Herruzo, Asunción Hervás, Alfredo Ramos, Víctor Macías, Josep Solé, Marta Bonet, Alfonso Mariño, Patricia Cabrera, Maria José Ortiz
近距离放射治疗（BT）和外束放射治疗（EBRT）是治疗高危前列腺癌（PCa）的有效方法。然而，这些治疗对健康相关生活质量（HRQL）的影响尚不清楚。在这项研究中，我们比较了EBRT单独与EBRT加高剂量率(HDR)-BT增强，以确定对高危PCa患者HRQL的影响。前瞻性、多中心研究比较2004年至2006年EBRT单独治疗或EBRT + HDR-BT治疗的高危PCa患者。在基线（治疗前）和5年随访期间定期评估HRQL，使用SF-36 （v.2）、EPIC、FACT-G和FACT-P问卷。研究共纳入129例患者，其中41例单独接受EBRT治疗，88例EBRT + HDR-BT治疗。所有患者均接受激素治疗。基线临床特征相似，除了EBRT组的平均合并症数量略高。随访期间，组间唯一显著差异是单独EBRT组EPIC激素域恶化更大（p = 0.028）。在5年的随访中，SF-36、FACT-G和FACT-P问卷或EPIC尿失禁、尿刺激-梗阻性、肠和性领域的治疗时间和相互作用没有显著差异。两组的肿瘤预后相似。经过5年的随访，EBRT单独或联合HDR-BT增强对高危局限性PCa患者的HRQL有相似的影响。然而，根据EPIC问卷，EBRT单独组患者的激素域恶化更大。
Brachytherapy (BT) and external beam radiation therapy (EBRT) are effective treatments for high-risk prostate cancer (PCa). However, the impact of these treatments on health-related quality of life (HRQL) remains unclear. In this study, we compared EBRT alone with EBRT plus a boost with high-dose rate (HDR)-BT to determine the impact on HRQL in patients with high-risk PCa. Prospective, multicenter study comparing patients with high-risk PCa treated with EBRT alone or EBRT + HDR-BT from 2004 to 2006. HRQL was assessed at baseline (pre-treatment) and periodically over the 5-year follow-up, using the SF-36 (v.2), EPIC, and FACT-G and FACT-P questionnaires. A total of 129 patients were included in the study, of these, 41 received EBRT alone and 88 EBRT + HDR-BT. All patients received hormonotherapy. Baseline clinical characteristics were similar, except for a slightly higher mean number of comorbidities in the EBRT group. During follow-up, the only significant between-group difference was a greater worsening on EPIC hormonal domain in the EBRT alone group (p = 0.028). There were no significant differences in time and interaction of treatment in SF-36, and FACT-G and FACT-P questionnaires or EPIC urinary incontinence, urinary irritative-obstructive, and bowel and sexual domains over the 5-year follow-up. Oncological outcomes were similar in both groups. After five years of follow-up, EBRT alone or combined with HDR-BT boost had a similar impact on HRQL in patients with high-risk localized PCa. However, patients in the EBRT alone group experienced greater worsening of hormonal domain according to EPIC questionnaire.
登录
查看更多内容
DOI：
10.1016/j.ijrobp.2014.09.044
发表时间：
2015-02-01
影响因子：
7
作者：
Avila, Monica;Becerra, Virginia;Ferrer, Montse
通讯作者：
Ferrer, Montse
影响因子：
120.7
作者：
Sheets, Nathan C.;Goldin, Gregg H.;Chen, Ronald C.
通讯作者：
Chen, Ronald C.
影响因子：
120.7
作者：
Chen, Ronald C.;Basak, Ramsankar;Godley, Paul A.
通讯作者：
Godley, Paul A.
影响因子：
1.9
作者：
Martinez, Evelyn;Daidone, Antonino;Guedea, Ferran
通讯作者：
Guedea, Ferran
DOI：
10.1056/nejmoa1606221
发表时间：
2016-10-13
期刊：
The New England journal of medicine
影响因子：
--
作者：
Donovan JL;Hamdy FC;Lane JA;Mason M;Metcalfe C;Walsh E;Blazeby JM;Peters TJ;Holding P;Bonnington S;Lennon T;Bradshaw L;Cooper D;Herbert P;Howson J;Jones A;Lyons N;Salter E;Thompson P;Tidball S;Blaikie J;Gray C;Bollina P;Catto J;Doble A;Doherty A;Gillatt D;Kockelbergh R;Kynaston H;Paul A;Powell P;Prescott S;Rosario DJ;Rowe E;Davis M;Turner EL;Martin RM;Neal DE;ProtecT Study Group*
通讯作者：
ProtecT Study Group*